HPV OncoPredict SIGNED
A Groundbreaking Stand-Alone Diagnostic Kit to Predict Human Papilloma Virus Infections Evolving into Cervical Cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0HPV OncoPredict project word cloud
Explore the words cloud of the HPV OncoPredict project. It provides you a very rough idea of what is the project "HPV OncoPredict" about.
Project "HPV OncoPredict" data sheet
The following table provides information about the project.
| Coordinator |
GENEFIRST LIMITED
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Project website | https://www.genefirst.com/hpv-oncopredict |
| Total cost | 2˙945˙000 € |
| EC max contribution | 2˙923˙061 € (99%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-09-01 to 2020-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GENEFIRST LIMITED | UK (ABINGDON) | coordinator | 1˙700˙000.00 |
| 2 | HIANTIS SRL | IT (MILAN) | participant | 1˙223˙061.00 |
Map
Project objective
Cervical cancer (CC) kills a 250,000 people annually, frequently affecting young women, and requires persistent infection with high-risk Human Papillomavirus (hrHPV) for its development. It is preventable, by HPV vaccination and the implementation of population screening programmes, and it is curable if detected and treated early. Despite overwhelming evidence that detection of viral nucleic acids (HPV testing) in cervical cellular samples allows earlier detection of CC as compared to cytology (Pap smear), it is feared that its use as a stand-alone test in CC screening would be responsible for over-diagnosis and over-treatment.
HPV OncoPredict is an innovative diagnostic device (IVD) capable of detecting all oncogenic hrHPV genotypes frequently causing cervical infection as well as allowing to accurate identification those 10% of infected women who are truly at risk of developing cervical cancer. With the use of novel viral biomarkers, HPV OncoPredict, starting from a single self- or clinician-collected cellular sample, will enable women to undergo both primary cervical screening and, if HPV-positive, subsequent triage. HPV OncoPredict will allow HPV testing to reliably replace Pap smears in cervical cancer prevention, as recently recommended by European guidelines, being based on a disruptive technology ahead of any competitor’s product and supported by key opinion leaders.
The HPV testing market is huge (€315 M) with around 100 million tests performed each year. The consortium formed by GeneFirst and Hiantis, both highly innovative companies with patented technologies, has the capacity to bring HPV OncoPredict to success. HPV OncoPredict will not only shape the manner in which we stratify women at risk of developing cervical cancer, but also provide an accurate and cost effective test of disease to benefit patients. More importantly, it will feed into how healthcare systems implement screening strategies to benefit patient pathways.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
M. Arbyn, E. Peeters, I. Benoy, D. Vanden Broeck, J. Bogers, P. De Sutter, G. Donders, W. Tjalma, S. Weyers, K. Cuschieri, M. Poljak, J. Bonde, C. Cocuzza, F.H. Zhao, S. Van Keer, A. Vorsters VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples published pages: 52-56, ISSN: 1386-6532, DOI: 10.1016/j.jcv.2018.08.006 |
Journal of Clinical Virology 107 | 2019-11-08 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HPV ONCOPREDICT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HPV ONCOPREDICT" are provided by the European Opendata Portal: CORDIS opendata.